Multicenter Comparative Study of the Activity of the Medial Prefrontal Cortex in Vulnerability to Depression (CORVAD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02171923|
Recruitment Status : Completed
First Posted : June 24, 2014
Last Update Posted : October 6, 2015
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||77 participants|
|Observational Model:||Case Control|
|Official Title:||Medial Prefrontal Cortex and Vulnerability for Depression|
|Study Start Date :||May 2013|
|Actual Primary Completion Date :||July 2015|
|Actual Study Completion Date :||July 2015|
Remitted depressed patients
Formerly depressed patients in remission for 6 months or more
healthy subjects with no history of mental disorders
- BOLD signal in the medial prefrontal cortex [ Time Frame: 18 month ]Each subject will have a standardized psychometric assessment (BDI-21, MADRS, STAI, RRS) in a Siemens 3T Trio for collecting voxel BOLD signal (Blood-Oxygen-Level Dependent). For each subject and each voxel, a coefficient beta relative activation will be obtained with a general linear model using the timing of presentation of stimuli and the expected signal to model the measured hemodynamic BOLD response. A main effect of condition (personal versus general) will be sought to determine the peak activation within the dorsal CMPF (defined region of interest using the Pickatlas software). The primary endpoint will be the beta coefficient on the level of activation of a sphere 10 mm in diameter centered on the peak.
- depression relapse [ Time Frame: 1 year ]The presence (MINI) and intensity (BDI) for possible depressive relapse will be sought from the attending psychiatrist and during telephone interviews at 6 and 12 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02171923
|URC - HEGP, 20 rue Leblanc|
|Paris, France, 75015|
|Principal Investigator:||Cédric Lemogne, MD, PhD||Assistance Publique - Hôpitaux de Paris|